Development & Clinical Application of K-PaC Registry Version 2.0

NCT ID: NCT07171515

Last Updated: 2025-09-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

6923 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-02

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Development and clinical use of pancreatic cancer registry

* Development of K-PaC Registry v.2.0: Retrospective data integration from 2010 to 2022 and prospective data collection from more than 811 enrolled patients from 2023 to 2029
* Creation of clinical evidence (RWE) based on pancreatic cancer real-world data (RWD): 3 or more

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We plan to collect retrospective and prospective data based on medical data centered on EMR. ∙ This registry is built on EMR data containing specific information on medical provider records and patient health records. It is designed to enable the confirmation of specific treatment history and medical staff records, and to generate highly valid RWD-based evidence through EMR information such as accurate diagnosis of disease, treatment method, symptom changes, monitoring of lab data values, and patient status. ∙ Based on the built registry data, it is possible to conduct research based on evaluation of drug treatment and additional comparison of indications for elderly or poor general condition patients who are excluded from regular clinical trials, as well as research on diagnosis and prognosis. The clinical information and biomarkers of the prospective patient group are analyzed to evaluate the correlation with treatment response, overall and progression-free survival rates.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of pancreatic cancer

Exclusion Criteria

* In cases where medical record review is not feasible
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Center, Korea

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sang Myung Woo

Head, Center for Liver and Pancreatobiliary Cancer

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Cancer Center

Goyang, Gyeonggido, South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.

Document Type: Study Protocol

1\. 1. Guidelines for the Pancreatic Cancer Registry, National Cancer Center Big Data

View Document

Document Type: Study Protocol

2\. CONNECT Cancer Big Data Library: Pancreatic Cancer Section

View Document

Document Type: Study Protocol

Korean clinical practice guideline for pancreatic cancer 2021

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://data.doi.or.kr/10.22694/CANCERDATA032018070101

1\. Guidelines for the Pancreatic Cancer Registry, National Cancer Center Big Data Center

https://cancerportal.kr/ncc/clinicalLibraryInfo.do

2\. CONNECT Cancer Big Data Library: Pancreatic Cancer Section

https://www.kahbps.or.kr/bbs/index.kin?bbs_mode=view&f_wbcode=board_request&f_master_idx=770&f_template_type=list

Korean clinical practice guideline for pancreatic cancer 2021: A summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCC2022-0061

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

SERum-bank for PANcreatic Cancer
NCT04374175 RECRUITING
The KN510713 Study in Combination With mFOLFIRINOX
NCT07114861 NOT_YET_RECRUITING PHASE1/PHASE2